Business
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
LOS ALTOS, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies
About this update from Unicycive Therapeutics, Inc.
[{"type":"text","content":"LOS ALTOS, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that a poster presentation on oxylanthanum carbonate (OLC) was selected for a Late-Breaker session at the American Society of Nephrology (ASN) Kidney Week 2024. Unicycive will also deliver three additional poster presentations on OLC and UNI-494. The conference will take place October 24-27, 2024 in San Diego, CA. Late Breaking Science Poster: Title:Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with HyperphosphatemiaLead Author:Geoffrey A. Block, MD, FASN, Associate Chief Medical Officer & Senior Vice President, Clinical Research & Medical Affairs, U.S. Renal CareSession Title:Late-Breaking Science Posters [LB-PO]Poster Board:#TH-PO1188Date/Time:Thursday, October 24, 2024 from 10:00 a.m. – 12:00 p.m. PT Three additional poster presentations: Title:Intravenous UNI-494 Slows the Progression or Halts/Reverses Acute Kidney Injury When Administered After Ischemia/Reperfusion in RatsLead Author:Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, UnicyciveSession Title:AKI: MechanismsPoster Board:#FR-PO155Date/Time:Friday, October 25, 2024 from 10:00 a.m. – 12:00 p.m. PT Title:Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in RatLead Author:Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, UnicyciveSession Title:CKD-MBD: Basic and TranslationalPoster Board:#SA-PO243Date/Time:Saturday, October 26, 2024 from 10:00 a.m. – 12:00 p.m. PT Title:UNI-494 Phase I Safety, Tolerability, and PharmacokineticsLead Author:Guru Reddy, PH.D., Vice President of Preclinical R&D, UnicyciveSession Title:AKI: Clinical, Outcomes, and Trials - ManagementPoster Board:#SA-PO036Date/Time:Saturday, October 26, 2024 from 10:00 a.m. – 12:00 p.m. PT About Oxylanthanum Carbonate (OLC) Oxylanthanum carbonate is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). OLC has over forty issued and granted patents globally. Its potential best-in-class profile may have meaningful patient ...